Login to Your Account



Other News To Note


Wednesday, December 14, 2011
• EnVivo Pharmaceuticals Inc., of Watertown, Mass., said the journal Neuropharmacology published data confirming the mechanism of action of its lead program EVP-6124 and demonstrating that the compound is a potent and highly selective agonist of alpha-7 neuronal nicotinic acetylcholine receptors in the brain.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription